Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Neurology

Topics

Medicine

Cancer Oncology

Immunology

Pathology

Internal Medicine

Show all topics

DOI

10.1016/s1474-4422(18)30069-3

Other Formats

PDF